IntoCell

IntoCell Total Assets

The Total Assets of IntoCell (287840.KQ) as of Nov 17, 2026 is 41.25 B KRW. In the previous year, Total Assets was 23.71 B KRW — a change of 73.98% (higher).

Total Assets

41.25 BKRW

YoY

73.98%

Last updated:

Total Assets of IntoCell is 2025 41.25 B KRW. Total Assets of IntoCell was 2024 23.71 B KRW. It decreases by 73.98% higher compared to the previous year.

The IntoCell Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2022
33.35 B KRW
Jan 1, 2023
25.94 B KRW
Jan 1, 2024
23.71 B KRW
Jan 1, 2025
41.25 B KRW
The IntoCell Total Assets history
YEARTotal AssetsYoY
41.25 BKRW+73.98%
23.71 BKRW-8.60%
25.94 BKRW-22.21%
33.35 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IntoCell Stock analysis

What does IntoCell do? IntoCell, Inc. generates revenue through the development and licensing of its ADC platform technologies, including the OHPAS linker technology and PMT platform technology. The company focuses on creating proprietary drug technologies for ADC development, targeting pharmaceutical companies seeking to improve drug delivery systems. Its primary customers are pharmaceutical firms interested in enhancing the efficacy and safety of antibody-drug conjugates through advanced linker and payload modification solutions. The OHPAS platform technology serves as a critical linker connecting drugs to antibodies, while the PMT platform technology reduces drug uptake into normal cells, addressing key challenges in ADC development. IntoCell's proprietary drug technology complements these platforms, offering specialized solutions for ADC manufacturers. The company's R&D-driven approach positions it as a provider of innovative tools for the biopharmaceutical industry. IntoCell's business model centers on technology licensing and development contracts with pharmaceutical partners. By leveraging its expertise in linker and payload modification, the company aims to secure long-term partnerships that drive revenue through milestone payments and royalties on commercialized products. The firm's focus on proprietary technologies ensures a competitive edge in the ADC market. IntoCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IntoCell stock

Total Assets of IntoCell is 41.25 B KRW in 2025.

Total Assets of IntoCell changed from 23.71 B KRW to 41.25 B KRW, representing a 73.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets IntoCell since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's IntoCell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — IntoCell

All Key Metrics — IntoCell